CNS Drugs
August 26, 2026
Alana King, Morgan S. Hardy, Taeho Greg Rhee et al.
Despite the wide prevalence of mood disorders globally, there is a substantial unmet need for effective, mechanistically distinct treatments. Given that approximately 30% of individuals do not display adequate response to standard antidepressant therapies, the past 15 years have seen a shift away from traditional monoaminergic approaches toward glutamatergic and other novel mechanisms....
Brazilian Journal of Implantology and Health Sciences
August 26, 2026
Kristen Garcia Costa, Gabriela Sensi Santhiago, Daniel Cardoso Madeira et al.
Introdução: O transtorno depressivo maior constitui uma importante causa de incapacidade e comprometimento da qualidade de vida. Entre os pacientes que não apresentam resposta adequada a tratamentos antidepressivos convencionais, destaca-se a depressão resistente ao tratamento, para a qual permanecem limitações terapêuticas relevantes. Nesse contexto, a cetamina e a esketamina surgiram como...
International Health Sciences Review
August 18, 2026
Samuel Cândido Freres, Marco Antonio Franco Cançado, Aline Ferreira Catrolio et al.
Treatment-resistant depression (TRD) represents one of the most complex forms of major depressive disorder, characterized by the persistence of clinically significant symptoms despite the performance of appropriate therapeutic interventions. This condition is associated with a worse prognosis, higher risk of recurrence, functional impairment, increased morbidity and mortality, and high...
Journal of Affective Disorders
August 15, 2026
Michał Walaszek, Wiesław Jerzy Cubała, Zofia Kachlik et al.
Anhedonia, a core symptom of major depressive disorder (MDD), is associated with illness severity, suicide risk, poor functioning, and predicts poor response to antidepressants. While no treatments are approved, ketamine and esketamine show promise in reducing anhedonia. This study examines clinical and sociodemographic features linked to anhedonia treatment response in treatment-resistant...
Journal of Medical Ethics
August 5, 2026
JingYi Zhang, Dominic Sisti
Intravenous ketamine and intranasal esketamine have shown rapid effects in reversing suicidality and improving depressive symptoms. In countries that allow psychiatric euthanasia and/or assisted suicide (EAS), we argue that potentially effective treatments for suicidal ideation and behaviour, such as ketamine, should be required before allowing patients to access psychiatric EAS. Ketamine can...
Journal of Pain and Symptom Management
August 1, 2026
Paul Noufi, Joshua B Borris, Danielle Chammas et al.
Patients with serious illnesses and short prognoses often experience depression and suicidal ideation. Traditional antidepressants are limited by delayed onset, creating a need for rapidly acting therapies. In this Palliative Care Rounds, we examine the evidence for ketamine/esketamine's efficacy as antidepressants, including evidence specific to people with serious illnesses. In psychiatric...
Current Pharmaceutical Design
July 31, 2026
Prachi Tayal, Rina Das, M.U. Khan et al.
BACKGROUND: Major depressive disorder (MDD) is one of the leading causes of disability globally, and conventional monoaminergic antidepressants often have a slow onset and limited efficacy. About onethird of patients suffer from treatment-resistant depression (TRD), which emphasizes the urgent need for alternative therapies. This review aims to systematically evaluate the available data about...
July 27, 2026
Asher Wenig, David B Newman
preprint
This project will use a PRISMA-guided systematic review and meta-analysis to examine whether age moderates anxiety and depression outcomes following psychoactive-assisted treatments. In this review, psychoactive-assisted treatments are defined as clinically structured treatments involving classic serotonergic psychedelics, MDMA, ketamine, or esketamine. The term is intentionally broader than...
Current Medical Research and Opinion
July 15, 2026
Anita H. Clayton, Gus Alva, Phillip Bowman et al.
OBJECTIVE: To establish consensus recommendations for initiating dextromethorphan-bupropion extended release (45 mg/105 mg) (AUVELITY) for the treatment of major depressive disorder (MDD) in adults. METHODS: = 10) with clinical experience treating MDD participated in a 3-stage modified Delphi panel procedure. An initial literature review was performed to assist in the development of draft...
Clinical Psychopharmacology and Neuroscience
July 14, 2026
Alessandro Serretti
The introduction of ketamine and its S-enantiomer, esketamine, has been one of the most consequential advances in treatment-resistant depression (TRD) in recent decades, demonstrating that rapid and clinically meaningful antidepressant effects can occur within hours, even in patients who have not responded to conventional treatments.However, this advance has not resolved the clinical problem of...